CA2851758A1 - Canine/feline cd20 binding epitope and compositions for binding thereto - Google Patents

Canine/feline cd20 binding epitope and compositions for binding thereto Download PDF

Info

Publication number
CA2851758A1
CA2851758A1 CA2851758A CA2851758A CA2851758A1 CA 2851758 A1 CA2851758 A1 CA 2851758A1 CA 2851758 A CA2851758 A CA 2851758A CA 2851758 A CA2851758 A CA 2851758A CA 2851758 A1 CA2851758 A1 CA 2851758A1
Authority
CA
Canada
Prior art keywords
amino acid
seq
acid sequence
antibody
identity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2851758A
Other languages
English (en)
French (fr)
Inventor
David Gearing
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nexvet Australia Pty Ltd
Original Assignee
NVIP Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NVIP Pty Ltd filed Critical NVIP Pty Ltd
Publication of CA2851758A1 publication Critical patent/CA2851758A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
CA2851758A 2011-10-13 2012-10-12 Canine/feline cd20 binding epitope and compositions for binding thereto Abandoned CA2851758A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161546865P 2011-10-13 2011-10-13
US61/546,865 2011-10-13
PCT/GB2012/052532 WO2013054127A1 (en) 2011-10-13 2012-10-12 Canine/feline cd20 binding epitope and compositions for binding thereto

Publications (1)

Publication Number Publication Date
CA2851758A1 true CA2851758A1 (en) 2013-04-18

Family

ID=47023030

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2851758A Abandoned CA2851758A1 (en) 2011-10-13 2012-10-12 Canine/feline cd20 binding epitope and compositions for binding thereto

Country Status (7)

Country Link
US (1) US20140294819A1 (enExample)
EP (1) EP2766391A1 (enExample)
JP (1) JP2015501146A (enExample)
AU (1) AU2012322445B2 (enExample)
CA (1) CA2851758A1 (enExample)
HK (1) HK1201281A1 (enExample)
WO (1) WO2013054127A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014368453B2 (en) 2013-12-20 2020-04-16 Intervet International B.V. Caninized murine anti-canine PD-1 antibodies
CA3014461C (en) 2016-02-18 2023-02-28 Elanco Us Inc. Chimeric canine anti-cd20 antibody
US11673961B2 (en) 2018-02-20 2023-06-13 Memorial Sloan Kettering Cancer Center Anti-CD20 antibody and uses thereof
CN114174336B (zh) * 2019-07-15 2024-10-11 英特维特国际股份有限公司 针对人和犬ctla-4的犬源化抗体
JP7671275B2 (ja) * 2019-08-29 2025-05-01 エランコ・ユーエス・インコーポレイテッド 動物用の抗ｉｌ３１抗体
JP2021059499A (ja) 2019-10-03 2021-04-15 日本全薬工業株式会社 イヌｃｄ２０に対するモノクローナル抗体又は抗体フラグメント
WO2022263864A1 (en) * 2021-06-17 2022-12-22 Petmedix Ltd Anti canine cd20 antibodies
AU2023379469A1 (en) * 2022-11-15 2025-05-22 Purdue Research Foundation Canine pd-l1 antibody, antigen binding fragments thereof, and methods of use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2469833C (en) * 2001-12-21 2008-05-20 Idexx Laboratories, Inc. Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them
JP4263951B2 (ja) * 2003-06-20 2009-05-13 財団法人日本生物科学研究所 イヌ化抗体の作成方法および使用
EP1751187A2 (en) * 2004-05-28 2007-02-14 Idexx Laboratories, Inc. Canine cd20 compositions
MX2010007515A (es) * 2008-01-11 2010-11-12 Chemo Sero Therapeut Res Inst Anticuerpo antiintegrina a9 humana humanizado mejorado.
EP2331579B1 (en) * 2008-09-04 2017-07-05 Vet Therapeutics, Inc. Monoclonal antibodies
WO2010117448A2 (en) * 2009-04-05 2010-10-14 Provenance Biopharmaceuticals Corp. Chimeric immunocytokines and methods of use thereof
EP2496604B1 (en) * 2009-11-06 2017-08-23 IDEXX Laboratories, Inc. Canine anti-cd20 antibodies

Also Published As

Publication number Publication date
HK1201281A1 (en) 2015-08-28
EP2766391A1 (en) 2014-08-20
NZ623644A (en) 2015-03-27
AU2012322445B2 (en) 2016-12-15
AU2012322445A1 (en) 2014-04-24
WO2013054127A1 (en) 2013-04-18
JP2015501146A (ja) 2015-01-15
US20140294819A1 (en) 2014-10-02

Similar Documents

Publication Publication Date Title
US12084499B2 (en) SIRP-α binding proteins and methods of use thereof
CN111051347B (zh) Tigit抗体、其抗原结合片段及医药用途
CN106029695B (zh) 拮抗性抗犬pd-1抗体
CN111744013B (zh) 抗tigit抗体联合pd-1抑制剂治疗疾病的方法和药物组合
AU2012322445B2 (en) Canine/feline CD20 binding epitope and compositions for binding thereto
TWI758558B (zh) Cd96抗體、其抗原結合片段及醫藥用途
CN107849136B (zh) 抗TfR抗体及其在治疗增殖性和炎性疾病中的用途
EP3424953B1 (en) Therapeutic antibodies
US20230120270A1 (en) New polypeptide complex
EP3744734A1 (en) Anti-4-1bb antibody, antigen-binding fragment thereof and medical use thereof
CN112513088B (zh) 抗ox40抗体、其抗原结合片段及其医药用途
EP3851456A1 (en) Anti-cd38 antibody, antigen-binding fragment thereof, and pharmaceutical use
TWI714895B (zh) 抗csf-1r抗體、其抗原結合片段及其醫藥用途
CN111788229A (zh) Csf1r结合剂
CN114174337A (zh) 针对犬ctla-4的犬源化抗体
US20250270346A1 (en) Efficacious anti-cd26 antibody biomarker
NZ623644B2 (en) Canine/feline cd20 binding epitope and compositions for binding thereto
HK40110110A (en) Canine antibodies having modified ch2-ch3 sequences
HK40038468A (en) Antibodies to lilrb2

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20171011

FZDE Discontinued

Effective date: 20200114